Page 1054 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Chapter 68

REFERENCES

1. Janeway CA Jr. Approaching the asymptote? Evolution and mortality, and associated costs of care. Crit Care. October
revolution in immunology. Cold Spring Harb Symp Quant Biol. 2004;8(5):R291-R298.
1989;54(pt 1):1-13. 14. Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent JL.
2. Medzhitov R. Recognition of microorganisms and acti- Characteristics and outcomes of cancer patients in European
vation of the immune response. Nature. October 18, ICUs. Crit Care. 2009;13(1):R15.
2007;449(7164):819-826. 15. Regazzoni CJ, Khoury M, Irrazabal C, et al. Neutropenia and
3. Azoulay E, Afessa B. The intensive care support of patients with the development of the systemic inflammatory response syn-
malignancy: do everything that can be done. Intensive Care drome. Intensive Care Med. 2003;29(1):135-138.
Med. January 2006;32(1):3-5. 16. Darmon M, Thiery G, Ciroldi M, et al. Intensive care in patients
4. Brenner H. Long-term survival rates of cancer patients achieved with newly diagnosed malignancies and a need for cancer che-
by the end of the 20th century: a period analysis. Lancet. motherapy. Crit Care Med. November 2005;33(11):2488-2493.
October 12, 2002;360(9340):1131-1135. 17. Benoit DD, Depuydt PO, Vandewoude KH, et al. Outcome
5. Ganz PA, Casillas J, Hahn EE. Ensuring quality care for cancer in severely ill patients with hematological malignancies who
survivors: implementing the survivorship care plan. Semin received intravenous chemotherapy in the intensive care unit.
Oncol Nurs. August 2008;24(3):208-217. Intensive Care Med. January 2006;32(1):93-99.
6. Groeger JS, White P Jr, Nierman DM, et al. Outcome for cancer 18. Shelton BK. Admission criteria and prognostication in patients
patients requiring mechanical ventilation. J Clin Oncol. March with cancer admitted to the intensive care unit. Crit Care Clin.
1999;17(3):991-997. January 2010;26(1):1-20.
7. Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA, 19. Haines IE, Zalcberg J, Buchanan JD. Not-for-resuscitation
Colardyn FA. Outcome and early prognostic indicators in orders in cancer patients—principles of decision-making. Med J
patients with a hematologic malignancy admitted to the inten- Aust. August 20 1990;153(4):225-229.
sive care unit for a life-threatening complication. Crit Care Med. 20. Schimpff SC. Dilemmas and choices in infection management
2003;31(1):104-112. of the cancer patient. Eur J Cancer Clin Oncol. September
8. Azoulay E, Pochard F, Chevret S, et al. Compliance with triage 1989;25(9):1351-1357.
to intensive care recommendations. Crit Care Med. November 21. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guide-
2001;29(11):2132-2136. line for the use of antimicrobial agents in neutropenic patients
9. Kress JP, Christenson J, Pohlman AS, Linkin DR, Hall JB. with cancer: 2010 update by the Infectious Diseases Society of
Outcomes of critically ill cancer patients in a university America. Clin Infect Dis. February 15, 2011;52(4):e56-e93.
hospital setting. Am J Respir Crit Care Med. December 1999; 22. Pizzo PA, Robichaud KJ, Wesley R, Commers J. Fever in the
160(6):1957-1961. pediatric and young adult patient with cancer—a prospective
10. Groeger JS, Aurora RN. Intensive care, mechanical ventila- study of 1001 episodes. Medicine. 1982;61(3):153-165.
tion, dialysis, and cardiopulmonary resuscitation: implications 23. Bow EJ, Rayner E, Scott BA, Louie TJ. Selective gut decontami-
for the patient with cancer. Crit Care Clin. July 2001;17(3): nation with nalidixic acid or trimethoprim-sulfamethoxazole for
791-803, x. infection prophylaxis in neutropenic cancer patients: relation-
11. Tanvetyanon T. Consideration before administering cytotoxic ship of efficacy to antimicrobial spectrum and timing of admin-
chemotherapy to the critically ill. Crit Care Med. November istration. Antimicrob Agents Chemother. 1987;31(4):551-557.
2005;33(11):2689-2691. 24. Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with
12. Azoulay E, Recher C, Alberti C, et al. Changing use of intensive cotrimoxazole for infection prophylaxis in acute leukemia:
care for hematological patients: the example of multiple myeloma. the trade-off for reduced gram-negative sepsis. Am J Med.
Intensive Care Med. December 1999;25(12):1395-1401. 1988;84(5):847-854.
13. Williams MD, Braun LA, Cooper LM, et al. Hospitalized 25. Group EIATCP. Ceftazidime combined with a short or long
cancer patients with severe sepsis: analysis of incidence, course of amikacin for empirical therapy of gram-negative

Section05-O-ref.indd 1 1/20/2015 4:51:18 PM